Bernstein lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $441 from $506 and keeps a Market Perform ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity” third ...

Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

William Pickering, an analyst from Bernstein, reiterated the Hold rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated ...

这一消息直接来自Vertex Pharmaceuticals Incorporated，报告的签署人是公司执行副总裁兼首席法务官Jonathan Biller。FDA对ALYFTREK的批准是Vertex Pharmaceuticals的一个重要进展，可能会加强公司在囊性纤维化治疗领域的产品组合。

CNBC’s Jim Cramer delivers his daily Mad Dash. Georgia appeals court removes Fani Willis from Trump 2020 election case Chip ...

Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed ...

The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.16% higher to $397.27 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.09% ...

Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...